In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia

BACKGROUND: Approximately fifty percent of patients with acute myeloid leukemia can be cured with current therapeutic strategies which include, standard dose chemotherapy for patients at standard risk of relapse as assessed by cytogenetic and molecular analysis, or high-dose chemotherapy with alloge...

Descripción completa

Detalles Bibliográficos
Autores principales: Minagawa, Kentaro, Jamil, Muhammad O., AL-Obaidi, Mustafa, Pereboeva, Larisa, Salzman, Donna, Erba, Harry P., Lamb, Lawrence S., Bhatia, Ravi, Mineishi, Shin, Di Stasi, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132227/
https://www.ncbi.nlm.nih.gov/pubmed/27907031
http://dx.doi.org/10.1371/journal.pone.0166891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132227/
https://www.ncbi.nlm.nih.gov/pubmed/27907031
http://dx.doi.org/10.1371/journal.pone.0166891

Ejemplares similares